Drug Type Synthetic peptide |
Synonyms RSO-021 |
Action inhibitors |
Mechanism 50S subunit inhibitors(50S ribosomal subunit inhibitors), FOXM1 inhibitors(forkhead box M1 inhibitors), PRDX3 inhibitors(peroxiredoxin 3 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationOrphan Drug (European Union) |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Malignant Pleural Effusion | Phase 2 | United Kingdom | 31 Mar 2022 | |
Malignant Pleural Effusion | Phase 2 | United Kingdom | 31 Mar 2022 | |
Malignant Pleural Mesothelioma | Phase 2 | United Kingdom | 31 Mar 2022 | |
Metastatic breast cancer | Phase 2 | United Kingdom | - | |
Non-Small Cell Lung Cancer | Phase 2 | United Kingdom | - | |
Ovarian Cancer | Phase 2 | United Kingdom | - | |
Adenocarcinoma of Lung | Phase 1 | United Kingdom | 30 Jan 2022 | |
Hormone receptor positive HER2 negative breast cancer | Preclinical | Taiwan Province | 17 Feb 2025 | |
Peritoneal Neoplasms | Preclinical | United Kingdom | 30 Jan 2022 |
Phase 1 | 15 | wvlsbmuurh(tyqiobkqer) = valdoqzjyz vjzyccprqv (ocjdlvwuig ) View more | Positive | 24 May 2024 | |||
wvlsbmuurh(tyqiobkqer) = vzhaoztfsy vjzyccprqv (ocjdlvwuig ) View more |